Type of leukemia-Chronic lymphocytic leukemia (CLL) Posts on Medivizor
Navigation Menu

Type of leukemia-Chronic lymphocytic leukemia (CLL) Posts on Medivizor

Promising early results with venetoclax in patients previously treated with idelalisib

Posted by on Jan 18, 2018 in Leukemia | 0 comments

In a nutshell This study examined venetoclax (Venclexta) for patients with chronic lymphocytic leukemia (CLL) previously treated with idelalisib (Zydelig). Researchers reported good response rates and a low rate of side effects for venetoclax after idelalisib. Some background Targeted therapy is the standard treatment of CLL. This includes the...

Read More

Good response rates to venetoclax in patients previously treated with ibrutinib

Posted by on Jan 12, 2018 in Leukemia | 0 comments

In a nutshell This study examined venetoclax (Venclexta) for patients with chronic lymphocytic leukemia (CLL) previously treated with ibrutinib (Imbruvica). Researchers reported good disease control and a low rate of side effects venetoclax after ibrutinib. Some background Targeted therapy is the standard treatment of CLL. This includes the Bruton...

Read More

CAR T-Cells and HIV: What’s the Connection?

CAR T-Cells and HIV: What’s the Connection?

Posted by on Jan 5, 2018 in Blog, Hodgkin's lymphoma, Leukemia, Lymphoma, Multiple Myeloma, Non-Hodgkin lymphoma | 0 comments

It has taken decades of work for researchers to find ways to activate the immune system to treat cancer (what we now call immuno-oncology or I-O). Much of that work has been poorly funded. Largely, it has been the result of researchers getting experience in other disciplines (like infectious disease) and then transferring that expertise to oncology...

Read More

What Are the Common Symptoms of CLL?

Posted by on Jan 3, 2018 in Leukemia | 0 comments

Video information: While some chronic lymphocytic leukemia (CLL) patients are asymptomatic, the disease can cause a wide range of symptoms—and indicate disease progression. Dr. Stephen Spurgeon, from the OHSU Knight Cancer Institute, describes common CLL symptoms and their implications. Transcript Please remember the opinions expressed on...

Read More

CLL With a 17p Deletion: What Is the Treatment Plan?

Posted by on Jan 3, 2018 in Leukemia | 0 comments

Video information: Precision medicine allows for treatment plans to line up with a specific genetic profile. Find out from Dr. Michael Keating what is used to target CLL patients with a 17p deletion and when treatment should generally start. Dr. Keating also shares other genetic mutations to be aware of, and which tests are used to locate...

Read More

Detecting, Identifying and Treating Subtypes of CLL

Posted by on Jan 3, 2018 in Leukemia | 0 comments

Video information: Every patient’s CLL is different, so how do doctors tell which CLL treatment is best? Dr. Kathryn Kolibaba, with Compass Oncology, and Dr. Stephen Spurgeon, from OHSU Knight Cancer Institute, discuss modern tests used to distinguish subtypes of CLL and find a therapy to match. The experts also share their thoughts on the...

Read More

Decoding Monoclonal Antibodies

Posted by on Jan 3, 2018 in Leukemia | 0 comments

Video information: What are monoclonal antibodies targeting in the fight against CLL? Join us to hear from experts, Dr. Stephen Spurgeon and Dr. Jeff Sharman, as they dissect the scientific terminology that describes the monoclonal antibody family and their intended targets in the body. Transcript: Andrew Schorr: We have all these other drugs...

Read More

An analysis comparing reduced-intensity conditioning and myeloablative therapy for CLL

Posted by on Dec 30, 2017 in Leukemia | 0 comments

In a nutshell This study analyzed the results of 37 studies comparing myeloablative therapy and reduced intensity conditioning (RIC) before stem cell transplantation in patients with chronic lymphocytic leukemia (CLL). This study concluded that RIC was associated with lower mortality and better survival compared to myeloablative therapy. Some...

Read More

A review of venetoclax for previously treated CLL

Posted by on Dec 2, 2017 in Leukemia | 0 comments

In a nutshell This study reviewed evidence on venetoclax (Venclexta) for previously treated chronic lymphocytic leukemia (CLL). Some background Targeted therapy is the standard treatment of CLL. This includes the BCL2 inhibitor therapy venetoclax. BCL2 inhibitor therapy blocks a protein called BCL2 involved in leukemia cell growth. Venetoclax has...

Read More

A look at tumor lysis syndrome in the treatment of CLL

Posted by on Nov 27, 2017 in Leukemia | 0 comments

In a nutshell This study reviewed the occurrence and management of tumor lysis syndrome in patients receiving treatment for chronic lymphocytic leukemia (CLL). Some background Tumor lysis syndrome (TLS) is an uncommon but potentially life-threatening complication associated with the treatment of some cancers. TLS occurs when a large number of...

Read More

Gender affects outcomes of rituximab-based treatment

Posted by on Nov 16, 2017 in Leukemia | 0 comments

In a nutshell This study examined the effect of gender on treatment outcomes with chemo-immunotherapy for chronic lymphocytic leukemia (CLL). Researchers reported better survival and disease progression outcomes for female patients receiving rituximab-based (Rituxan) therapy.  Some background Men are more likely to develop CLL than women....

Read More